Mechanisms of ganglion cell injury in glaucoma
青光眼神经节细胞损伤的机制
基本信息
- 批准号:nhmrc : 400127
- 负责人:
- 金额:$ 19.97万
- 依托单位:
- 依托单位国家:澳大利亚
- 项目类别:NHMRC Project Grants
- 财政年份:2006
- 资助国家:澳大利亚
- 起止时间:2006-01-01 至 2008-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The aim of this project is to improve our understanding of the role that increased eye pressure (intraocular pressure or IOP) plays in the development of glaucoma-related nerve death and associated vision loss. Despite being the second leading cause of vision loss in Australia, our understanding of the factors that damage nerves in the eye (the ganglion cells that carry visual information to the brain) in glaucoma remains incomplete. For example, elevated eye pressure is a well-established risk factor for glaucoma, but as many as half of those with glaucoma do not have high eye pressure. Clinical data suggests that pressure fluctuations (or spikes), which go unnoticed in routine clinical check ups, may be involved in glaucoma onset and progression. To date there has been no direct evidence to support this contention. This project aims to use a novel experimental model of pressure elevation in rodents to consider this possibility. By measuring the eye's electrical response to a flash of light it is possible to sensitively assess how pressure spikes, that are known to occur with regularity in humans, might affect the health of retinal ganglion cells. Anatomical measures will also be used to establish the sequence of events that cause cellular damage. This knowledge is an important public health issue, because it will improve understanding of the risk factors for the development of glaucoma. The results may lead to improvements in detection and treatment strategies such as closer monitoring for pressure spikes and more aggressive treatment for those who show greater variability in their eye pressures.
该项目的目的是提高我们对眼压升高(眼内压或IOP)在青光眼相关神经死亡和相关视力丧失发展中的作用的理解。尽管青光眼是澳大利亚视力丧失的第二大原因,但我们对青光眼损伤眼睛神经(向大脑传递视觉信息的神经节细胞)的因素的了解仍然不完整。例如,眼压升高是青光眼的一个公认的危险因素,但多达一半的青光眼患者并没有眼压高。临床资料表明,在常规临床检查中未被注意到的压力波动(或尖峰)可能与青光眼的发生和发展有关。到目前为止,还没有直接证据支持这一论点。本项目旨在使用一种新的啮齿动物压力升高实验模型来考虑这种可能性。通过测量眼睛对闪光的电反应,有可能敏感地评估压力峰值是如何影响视网膜神经节细胞的健康的,这种压力峰值已知在人类中有规律地发生。解剖方法也将用于确定引起细胞损伤的事件序列。这是一个重要的公共卫生问题,因为它将提高对青光眼发展危险因素的认识。研究结果可能会改善检测和治疗策略,比如更密切地监测眼压峰值,对那些眼压变化较大的人进行更积极的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A/Pr Bang Bui其他文献
A/Pr Bang Bui的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A/Pr Bang Bui', 18)}}的其他基金
The role of microglia in early diabetic retinopathy
小胶质细胞在早期糖尿病视网膜病变中的作用
- 批准号:
nhmrc : GNT1138509 - 财政年份:2018
- 资助金额:
$ 19.97万 - 项目类别:
Project Grants
The role of microglia in early diabetic retinopathy
小胶质细胞在早期糖尿病视网膜病变中的作用
- 批准号:
nhmrc : 1138509 - 财政年份:2018
- 资助金额:
$ 19.97万 - 项目类别:
Project Grants
Novel ways of treating angiogenesis in the eye
治疗眼部血管生成的新方法
- 批准号:
nhmrc : GNT1113654 - 财政年份:2016
- 资助金额:
$ 19.97万 - 项目类别:
Development Grants
Novel ways of treating angiogenesis in the eye
治疗眼部血管生成的新方法
- 批准号:
nhmrc : 1113654 - 财政年份:2016
- 资助金额:
$ 19.97万 - 项目类别:
Development Grants
Minimally-invasive gene delivery of a novel inhibitor of retinal angiogenesis
新型视网膜血管生成抑制剂的微创基因递送
- 批准号:
nhmrc : 1061912 - 财政年份:2014
- 资助金额:
$ 19.97万 - 项目类别:
Project Grants
AGE-RELATED IMPAIRMENT OF AUTOREGULATION: A MODIFIABLE RISK FACTOR FOR GLAUCOMA
与年龄相关的自动调节损伤:青光眼的一个可改变的风险因素
- 批准号:
nhmrc : 1046203 - 财政年份:2013
- 资助金额:
$ 19.97万 - 项目类别:
Project Grants
Understanding the genetic determinants of central corneal thickness and its functional role in glaucoma pathophysiology
了解中央角膜厚度的遗传决定因素及其在青光眼病理生理学中的功能作用
- 批准号:
nhmrc : 535077 - 财政年份:2009
- 资助金额:
$ 19.97万 - 项目类别:
NHMRC Project Grants
OCULAR PERFUSION PRESSURE: A MODIFIABLE RISK FACTOR FOR GLAUCOMA?
眼灌注压:青光眼的一个可改变的危险因素?
- 批准号:
nhmrc : 566570 - 财政年份:2009
- 资助金额:
$ 19.97万 - 项目类别:
NHMRC Project Grants
Effect of aging and mitochondrial dysfunction on the optic nerve response to pressure-induced oxidative stress
衰老和线粒体功能障碍对视神经对压力诱导的氧化应激反应的影响
- 批准号:
nhmrc : 475603 - 财政年份:2008
- 资助金额:
$ 19.97万 - 项目类别:
NHMRC Project Grants
相似国自然基金
背根神经节中Mrgprd通过一种特异性lncRNA调控阿片类药物耐受的外周机制研究
- 批准号:82371224
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
相似海外基金
Developmental mechanisms specifying vagal innervation of organ targets
指定器官目标迷走神经支配的发育机制
- 批准号:
10752553 - 财政年份:2024
- 资助金额:
$ 19.97万 - 项目类别:
Antiarrhythmic mechanisms of chronic vagal nerve stimulation in sympathetic neurons
交感神经元慢性迷走神经刺激的抗心律失常机制
- 批准号:
10635151 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
The Underlying Mechanisms of Visual Impairment and Myopia in Prematurity
早产儿视力障碍和近视的潜在机制
- 批准号:
10584723 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
Mechanisms of NMDAR contribution to traumatic injury in retinal ganglion cells
NMDAR对视网膜神经节细胞创伤性损伤的作用机制
- 批准号:
10570666 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTA
小肠微生物驱动内脏疼痛的机制
- 批准号:
10836298 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
Investigating the mechanisms of stereocilia length regulation and innovative strategies for restoring hearing
研究静纤毛长度调节机制和恢复听力的创新策略
- 批准号:
10678569 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
Synaptic mechanisms and circuitry of retinal interneurons
视网膜中间神经元的突触机制和电路
- 批准号:
10737233 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
Myopia and Glaucoma, Linked via Mechanotransduction Mechanisms Affecting the Ganglion Cell Complex
近视和青光眼通过影响神经节细胞复合体的机械传导机制联系起来
- 批准号:
10656793 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
Evaluating Mechanisms and Therapeutic Potential of (GLP-1R) Agonists for Glaucoma Treatment
评估 (GLP-1R) 激动剂治疗青光眼的机制和治疗潜力
- 批准号:
10660124 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别:
Mechanisms of microglial neuroinflammatory response in glaucoma
青光眼小胶质细胞神经炎症反应机制
- 批准号:
10717247 - 财政年份:2023
- 资助金额:
$ 19.97万 - 项目类别: